Get the Stockscreener App
2.21
2.31%
0.05
After Hours:
2.22
0.01
+0.45%
Citius Oncology Inc stock is traded at $2.21, with a volume of 380.44K.
It is up +2.31% in the last 24 hours and down -49.20% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$2.16
Open:
$2.22
24h Volume:
380.44K
Relative Volume:
0.26
Market Cap:
$173.20M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+13.33%
1M Performance:
-49.20%
6M Performance:
+84.01%
1Y Performance:
+0.00%
1-Day Range:
$2.19
$2.33
1-Week Range:
$1.75
$2.3791
52-Week Range:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
2.21 | 169.28M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
How strong is Citius Oncology Inc. company’s balance sheetBest Dividend Report For Fast Growth - jammulinksnews.com
What are analysts’ price targets for Citius Oncology Inc. in the next 12 monthsPost Market Review For 2025 - jammulinksnews.com
How does Citius Oncology Inc. generate profit in a changing economyPost Market Target Finder To Watch Now - jammulinksnews.com
What makes Citius Oncology Inc. stock attractive to long term investorsPortfolio Diversification Stock Ideas From Experts - metal.it
Published on: 2025-07-29 19:38:23 - metal.it
Trendline Breach Raises Concern for Citius Oncology Inc. InvestorsFundamental + Technical Hybrid Stock Tips Shared - metal.it
Should I hold or sell Citius Oncology Inc. stock in 2025Market Forecast Picks That Work - jammulinksnews.com
What is Citius Oncology Inc. company’s growth strategyTremendous portfolio expansion - jammulinksnews.com
How does Citius Oncology Inc. compare to its industry peersAchieve breakthrough results with expert guidance - jammulinksnews.com
What is the risk reward ratio of investing in Citius Oncology Inc. stockMassive stock growth - jammulinksnews.com
Does Citius Oncology Inc. stock perform well during market downturnsInvest smarter with data-backed insights - jammulinksnews.com
What are the latest earnings results for Citius Oncology Inc.Build a winning portfolio with smart picks - jammulinksnews.com
Citius Oncology Inc. Stock Support and Resistance Levels You Should KnowVerified Return Tips - metal.it
Is Citius Oncology Inc. a good long term investmentExceptional trading performance - Autocar Professional
What drives Citius Oncology Inc. stock priceDynamic growth stocks - Autocar Professional
Citius Oncology Announces Closing of $9.0 Million Public Offering - StreetInsider
Citius Oncology Inc. Stock Analysis and ForecastMarket-leading capital gains - Autocar Professional
Citius Oncology shares surge 50.91% intraday after signing LYMPHIR distribution agreement with Cencora. - AInvest
What analysts say about Citius Oncology Inc. stockFree Wealth Management Insights - jammulinksnews.com
Citius Oncology shares rise 1.31% after-hours after closing a $9.0 million public offering. - AInvest
Should I buy Citius Oncology Inc. stock before earningsShort Term High Return Strategy - Newser
Citius Oncology Completes $9M Public Offering - TipRanks
Cencora, Inc. shares rise 2.42% after-hours following Citius Oncology's $9.0 million public offering. - AInvest
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):